
Marksans Pharma shares in focus after block deals worth ₹257 crore
As of the March-end quarter, OrbiMed Asia IV Mauritius FVCI Ltd had a 10.88% stake in Marksans Pharma.

As of the March-end quarter, OrbiMed Asia IV Mauritius FVCI Ltd had a 10.88% stake in Marksans Pharma.

On Wednesday, market tech analyst Mitessh Thakkar recommended these stocks for the short term.

Eternal Block Deal: Shares changed hands at an average price of ₹256 per share, implying a total transaction value of ₹156 crore.

Sula Vineyards shares, which have been underperformers for a long period of time, have also gained as wine, as a category, is not mentioned in…

South Asia Growth Fund was indeed the seller in the Premier Energies transaction, as reported by CNBC-TV18 earlier. At the end of the March quarter,…

This is the highest-ever increase in duty in percentage terms in Maharashtra since 2011. As a result of this increase in duty, the Maximum Retail…

HSBC has maintained a ‘Neutral’ stance on India from an Asian portfolio perspective, with the 2025-end index target of 82,240 for the Sensex.

For the financial year 2024, the Operating Asset Management segment contributed approximately 15% to Quess Corp’s total revenue and 20% to its Earnings Before Interest,…

Talks in London came after the US and China accused each other of reneging on a deal reached in May in Geneva, where they tried…

AB Capital Share Price | On Tuesday, June 10, CNBC-TV18 reported, citing resources that Jomei Investments, a special purpose vehicle owned by Advent International Corporation,…